Background: Limited data regarding efficacy, safety, and optimal dose of nonvitamin K
antagonist oral anticoagulants (NOAC) in Asian patients with nonvalvular atrial fibrillation …

Background and Purpose—Limited data are available describing the relative effectiveness,
safety, and optimal dosing of non–vitamin K antagonist oral anticoagulants (NOACs) for …

Objective To assess the safety (ie, risk of bleeding) and effectiveness (ie, risk of
stroke/systemic embolism (SE)) separately for four non-vitamin K oral anticoagulants …

Introduction: Non-vitamin K oral anticoagulants (NOACs) were shown to have better
outcomes than warfarin for non-valvular atrial fibrillation (NVAF). Given limited local …

Reduced-dose nonvitamin K antagonist oral anticoagulants (NOACs) are commonly
prescribed to Asian patients with nonvalvular atrial fibrillation (NVAF). We aimed to compare …

Background: The J-RHYTHM Registry 2 was a multicenter, prospective observational study
that extended the follow-up period of the J-RHYTHM Registry in order to investigate long …

Background Although the majority of clinical guidelines indicate the use of NOAC
(nonvitamin K antagonist oral anticoagulant) over vitamin K antagonist in nonvalvular atrial …

Background: Non-vitamin K antagonist oral anticoagulants (NOAC) have been developed as
alternatives to warfarin. Until recently, the latter was the standard oral anticoagulant for …

Background: The meta-analysis of randomized controlled trials has illustrated that the
efficacy of low-dose non-vitamin K antagonist oral anticoagulants is inferior compared with …

Background: Non-vitamin K antagonist oral anticoagulants (NOAC) have been developed as
alternatives to warfarin. Until recently, the latter was the standard oral anticoagulant for …